STAGE IIIB OVARIAN CANCER AJCC V8
Clinical trials for STAGE IIIB OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIB OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy drug shows promise for hard-to-treat cancers with genetic flaws
Disease control OngoingThis study tests the drug pembrolizumab in people with advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. About 21 adults with metastatic or recurrent cancer took part. Pembrolizu…
Matched conditions: STAGE IIIB OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tested the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they had surgery. The goal was to see if taking olaparib for two cycles could shrink tumors or stop them from growing. Olaparib works…
Matched conditions: STAGE IIIB OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
Can we predict who will get nerve damage from chemo?
Knowledge-focused OngoingThis study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …
Matched conditions: STAGE IIIB OVARIAN CANCER AJCC V8
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:04 UTC